# Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa

> **NCT00383903** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 472 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** HRV vaccine

## Key facts

- **NCT ID:** NCT00383903
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383903, "Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00383903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*